S. 854: Risky Research Review Act
The "Risky Research Review Act" aims to enhance oversight of federal funding for high-risk life sciences research by establishing the Life Sciences Research Security Board. This Board will ensure that all federally funded projects comply with established safety standards, particularly with regard to research that may involve dual-use and gain-of-function studies, which can have implications for both medical advancements and potential biosecurity risks.
Board Composition and Responsibilities
The Life Sciences Research Security Board will be composed of appointed members who are experts in various relevant fields, ensuring that the oversight is informed by knowledgeable individuals. The Board's main responsibilities include:
- Establishing necessary review procedures to evaluate high-risk research within 180 days after the appointment of its members.
- Consulting with Congress before implementing its review procedures to ensure transparency and alignment with legislative expectations.
- Commencing its oversight duties within 270 days of member appointment.
- Responding to any inquiries from Congress within 30 days to maintain accountability.
- Providing quarterly updates on its activities and findings.
- Finalizing its authority regarding classifications of high-risk life sciences research.
Implications of the Act
The creation of the Life Sciences Research Security Board is intended to address concerns around the safety and ethical implications of high-risk life sciences research. By implementing a structured review process, the Act seeks to mitigate risks associated with research that could potentially lead to harmful outcomes if mismanaged or improperly conducted.
Relevant Companies
- AMGN (Amgen Inc.): As a biotechnology company, Amgen may be impacted due to its involvement in various life sciences research projects, particularly those that could be classified as high-risk under the new oversight.
- NVTA (Invitae Corporation): Invitae's work in genetic testing and personalized medicine could be subject to the Board's regulatory framework, especially in high-risk areas related to genetic research.
- REGN (Regeneron Pharmaceuticals): Regeneron's research into advanced therapeutics might be affected by the provisions set forth in this Act, depending on the nature of its projects that fall under high-risk classifications.
This is an AI-generated summary of the bill text. There may be mistakes.
Sponsors
2 bill sponsors
Actions
5 actions
| Date | Action |
|---|---|
| Sep. 17, 2025 | Committee on Homeland Security and Governmental Affairs. Reported by Senator Paul without amendment. Without written report. |
| Sep. 17, 2025 | Placed on Senate Legislative Calendar under General Orders. Calendar No. 164. |
| Jul. 30, 2025 | Committee on Homeland Security and Governmental Affairs. Ordered to be reported without amendment favorably. |
| Mar. 05, 2025 | Introduced in Senate |
| Mar. 05, 2025 | Read twice and referred to the Committee on Homeland Security and Governmental Affairs. |
Corporate Lobbying
0 companies lobbying
None found.
* Note that there can be significant delays in lobbying disclosures, and our data may be incomplete.
